systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-698Research ArticleСТАТЬИARTICLESСовременные аспекты
фармакотерапии артериальной
гипертензии. Возможности урапидилаМорозоваТ. Е.noemail@neicon.ruГОУ ВПО Первый московский государственный медицинский университет им. И.М.Сеченова Минздравсоцразвития РФRussian Federation201109022023831620Copyright © Морозова Т.Е., 20232023Морозова Т.Е.Морозова Т.Е.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/698ReferencesШальнова С.А., Баланова Ю.А., Константинов В. В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. РКЖ. 2006; 4: 45-50.Шальнова С.А., Баланова Ю.А., Константинов В. В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. РКЖ. 2006; 4: 45-50.Ezzati M, Lopez A, Rodgers A, Vander Hoorn S et al. Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors. Ge-neva: World Health Organization 2004.Ezzati M, Lopez A, Rodgers A, Vander Hoorn S et al. Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors. Ge-neva: World Health Organization 2004.Chobanian AV. Shattuck Lecture. The hypertension paradox - more uncontrolled disease de-spite improved therapy. N Engl J Med 2009; 361: 878-87.Chobanian AV. Shattuck Lecture. The hypertension paradox - more uncontrolled disease de-spite improved therapy. N Engl J Med 2009; 361: 878-87.Диагностика и лечение артериальной гипертонии. Рекомендаци РМОАГ/ВНОК, четвертый пересмотр. 2010.Диагностика и лечение артериальной гипертонии. Рекомендаци РМОАГ/ВНОК, четвертый пересмотр. 2010.Hunt KJ, Resendez RG, Williams K et al. San Antonio Heart StudyNational Cho-lesterol Edu-cation Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110 (10): 1251-7.Hunt KJ, Resendez RG, Williams K et al. San Antonio Heart StudyNational Cho-lesterol Edu-cation Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110 (10): 1251-7.Stamler J, Vaccaro O, Neaton JD et al. for the Multiple Risk Factor Intervention Trial Re-search Group. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-44.Stamler J, Vaccaro O, Neaton JD et al. for the Multiple Risk Factor Intervention Trial Re-search Group. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-44.Parving H.H. Hypertension and diabetes: the scope of the problem. Blood pressure 2001; 10 (Suppl. 2): 25-31.Parving H.H. Hypertension and diabetes: the scope of the problem. Blood pressure 2001; 10 (Suppl. 2): 25-31.Мancia G, Grassi G, Zanchetti A. Newonset diabetes and antihypertensive drugs. J Hypertens 2006; 24: 3-10.Мancia G, Grassi G, Zanchetti A. Newonset diabetes and antihypertensive drugs. J Hypertens 2006; 24: 3-10.Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network metaanalysis. Lancet 2007; 369: 201-7.Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network metaanalysis. Lancet 2007; 369: 201-7.Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arte-rial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-536.Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arte-rial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-536.Zusman RM. The role of alpha 1-blockers in combination therapy for hypertension. Int J Clin Pract 2000; 54: 36-40.Zusman RM. The role of alpha 1-blockers in combination therapy for hypertension. Int J Clin Pract 2000; 54: 36-40.Verdecchia P, Staessen JA, Angeli F et al. Usual versus tight control of systolic blood pres-sure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009; 374 (9689): 525-33.Verdecchia P, Staessen JA, Angeli F et al. Usual versus tight control of systolic blood pres-sure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009; 374 (9689): 525-33.van Zwieten PA, Blauw GJ, van Brummelen P. Pharmacological profile of anti-hypertensive drugs with serotonin receptor and alpha-adrenoceptor activity. Drugs 1990; 40 (Suppl. 4): 1-8.van Zwieten PA, Blauw GJ, van Brummelen P. Pharmacological profile of anti-hypertensive drugs with serotonin receptor and alpha-adrenoceptor activity. Drugs 1990; 40 (Suppl. 4): 1-8.Heran BS, Galm BP, Wright JM. Blood pressure lowering efficacy of alpha blockers for pri-mary hypertension. Cochrane Database Syst Rev 2009; 4: CD004643.Heran BS, Galm BP, Wright JM. Blood pressure lowering efficacy of alpha blockers for pri-mary hypertension. Cochrane Database Syst Rev 2009; 4: CD004643.Fozard JR, Mir AK. Are 5HT-receptors involved in the antihypertensive effects of urapidil. Brit J Pharmacol 1987; 90: 24P.Fozard JR, Mir AK. Are 5HT-receptors involved in the antihypertensive effects of urapidil. Brit J Pharmacol 1987; 90: 24P.Gross G, Hanft G, Kolassa N. Urapidil and some analogues with hypotensive properties show high affinities for 5-hydroxytryptamine (5HT) binding sites of the 5HT1A-sub-type and for a1-adrenoceptor binding sites. Naunyn-Schmiedeberg. Arch Pharmacol 1987; 336: 597-601.Gross G, Hanft G, Kolassa N. Urapidil and some analogues with hypotensive properties show high affinities for 5-hydroxytryptamine (5HT) binding sites of the 5HT1A-sub-type and for a1-adrenoceptor binding sites. Naunyn-Schmiedeberg. Arch Pharmacol 1987; 336: 597-601.Giilis RA, Kellar KJ, Quest JA et al. Experimental studies on the neurocardiovas-cular ef-fects of urapidil. Drugs 1988; 35 (Suppl. 6): 20-33.Giilis RA, Kellar KJ, Quest JA et al. Experimental studies on the neurocardiovas-cular ef-fects of urapidil. Drugs 1988; 35 (Suppl. 6): 20-33.Kolassa N, Beller KD, Sanders KH. Involvement of brain 5HT1A-receptors in the hypoten-sive response to urapidil. Am J Cardiol 1989; 64: 7-10D.Kolassa N, Beller KD, Sanders KH. Involvement of brain 5HT1A-receptors in the hypoten-sive response to urapidil. Am J Cardiol 1989; 64: 7-10D.Sanders KH, Beller KD, Eltze M et al. Urapidil and some anaglogs with high affinities for serotonin-1A and b1-adrenoceptor binding sites show potent hypotensive activity upon central administration. Current Оpinion Cardiol 1989; 4 (Suppl. 4): S49-55.Sanders KH, Beller KD, Eltze M et al. Urapidil and some anaglogs with high affinities for serotonin-1A and b1-adrenoceptor binding sites show potent hypotensive activity upon central administration. Current Оpinion Cardiol 1989; 4 (Suppl. 4): S49-55.Fariello R, Boni E, Corda L, Zaninelli A et al. Influence of a new multifactorial antihyperten-sive on blood pressure and metabolic profile in essential hypertension associated with non-insulin-dependent diabetes mellitus. Eur Heart J 1992; 13 (Suppl. A): 65-9.Fariello R, Boni E, Corda L, Zaninelli A et al. Influence of a new multifactorial antihyperten-sive on blood pressure and metabolic profile in essential hypertension associated with non-insulin-dependent diabetes mellitus. Eur Heart J 1992; 13 (Suppl. A): 65-9.Oren S, Turkot S, Paran E, Flandra O et al. Efficacy and tolerability of slow release urapidil (ebrantil) in hypertensive patients with non-insulin dependent diabetes mellitus (NIDDM). J Hum Hypertens 1996; 10: 123-7.Oren S, Turkot S, Paran E, Flandra O et al. Efficacy and tolerability of slow release urapidil (ebrantil) in hypertensive patients with non-insulin dependent diabetes mellitus (NIDDM). J Hum Hypertens 1996; 10: 123-7.Goto Y. Effects of sustained-release urapidil on essential hypertension and hyperlipidaemia: a multicenter clinical trial. Curr Ther Res 1992; 51: 870-6.Goto Y. Effects of sustained-release urapidil on essential hypertension and hyperlipidaemia: a multicenter clinical trial. Curr Ther Res 1992; 51: 870-6.Ferrara LA, Leonetti G, Fogari R, Mazzola C et al. Urapidil in hypercholesterolemic hyper-tensive patients. Blood Press Suppl 1994; 4: 39-44.Ferrara LA, Leonetti G, Fogari R, Mazzola C et al. Urapidil in hypercholesterolemic hyper-tensive patients. Blood Press Suppl 1994; 4: 39-44.Pattenier JW, von Heusinger FC. Effect of urapidil treatment on lipid metabolism in patients with hypertension. Royal Soc Med Int Congr Symp 1992; 196: 61-7.Pattenier JW, von Heusinger FC. Effect of urapidil treatment on lipid metabolism in patients with hypertension. Royal Soc Med Int Congr Symp 1992; 196: 61-7.Alijotas-Reig J, Bove-Farre I, De Cabo-Frances F et al. Effectiveness and safety of prehospi-tal urapidil for hypertensive emergencies. Am J Emerg Med 2001; 19: 130-3.Alijotas-Reig J, Bove-Farre I, De Cabo-Frances F et al. Effectiveness and safety of prehospi-tal urapidil for hypertensive emergencies. Am J Emerg Med 2001; 19: 130-3.Cherney D, Strans Sh. Management of patients with hypertensive urgencies and emergen-cies. J Gen Intern Med 2002; 17: 937-94.Cherney D, Strans Sh. Management of patients with hypertensive urgencies and emergen-cies. J Gen Intern Med 2002; 17: 937-94.Елагин Р.И. Адренергические средства: альфа-адреноблокаторы. Cons. Med. 2003; 7: 1-6.Елагин Р.И. Адренергические средства: альфа-адреноблокаторы. Cons. Med. 2003; 7: 1-6.Rosei EA, Salvetti M, Farsang C. Лечение осложненных и неосложненных гипертонических кризов. Актуальные вопросы болезней сердца и сосудов. 2007; 2: 66-8.Rosei EA, Salvetti M, Farsang C. Лечение осложненных и неосложненных гипертонических кризов. Актуальные вопросы болезней сердца и сосудов. 2007; 2: 66-8.Liebau H, Wurst W, Harder I, Solleder P. Metabolically neutral therapy of hyper-tension. An open, multicenter, prospective long-term study of the tolerance, safety and effective-ness of ura-pidil. Fortschr Med 1988; 106: 651-4.Liebau H, Wurst W, Harder I, Solleder P. Metabolically neutral therapy of hyper-tension. An open, multicenter, prospective long-term study of the tolerance, safety and effective-ness of ura-pidil. Fortschr Med 1988; 106: 651-4.Liebau H, Solleder P, Harder I, Wurst W. Long-term antihypertensive therapy with urapidil. A 3-year open, multicenter trial of tolerance, safety and effectiveness. Fortschr Med 1990; 108: 325-28.Liebau H, Solleder P, Harder I, Wurst W. Long-term antihypertensive therapy with urapidil. A 3-year open, multicenter trial of tolerance, safety and effectiveness. Fortschr Med 1990; 108: 325-28.Haerlin R. Treatment of primary and secondary hypertension. Long-term use of urapidil (Ebrantil®). Clinical Trials J 1985; 22: 215-25.Haerlin R. Treatment of primary and secondary hypertension. Long-term use of urapidil (Ebrantil®). Clinical Trials J 1985; 22: 215-25.Dooley M, Goa KL. Urapidil. A reappraisal of its use in the management of hypertension. Drugs 1998; 56: 929-55.Dooley M, Goa KL. Urapidil. A reappraisal of its use in the management of hypertension. Drugs 1998; 56: 929-55.Zanchetti A. Addition of urapidil or metoprolol to the treatment of hypertensive non-responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group. Blood Press Suppl 1995; 3: 38-46.Zanchetti A. Addition of urapidil or metoprolol to the treatment of hypertensive non-responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group. Blood Press Suppl 1995; 3: 38-46.
The authors declare that there are no conflicts of interest present.